Current treatment status-Undergoing active treatment-No response Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-No response Posts on Medivizor

Does a dose of 20 or 25 mg/m2 of cabazitaxel benefit patients with castration-resistant prostate cancer?

Does a dose of 20 or 25 mg/m2 of cabazitaxel benefit patients with castration-resistant prostate cancer?

Posted by on Sep 8, 2020 in Prostate cancer | 0 comments

In a nutshell This study aimed to assess the effectiveness and safety of two doses of cabazitaxel  (Jevtana) (20 or 25 mg/m2) in the treatment of castration-resistant prostate cancer (CRPC) in the real-world practice. The study found that a lower dose of cabazitaxel benefited patients at high risk of having side...

Read More

Looking for patients with metastatic non-small cell lung cancer to trial a biological treatment combination

Looking for patients with metastatic non-small cell lung cancer to trial a biological treatment combination

Posted by on Aug 30, 2020 in Lung cancer | 0 comments

In a nutshell This trial is being carried out to assess the effectiveness of atezolizumab (Tecentriq) in combination with cabozantinib (Cabometyx) versus docetaxel (Taxotere) in patients with metastatic non-small cell lung cancer (NSCLC) which has previously been treated with immunotherapy and platinum-based chemotherapy....

Read More

MTX-HOPE chemotherapy for patients over 70 with relapsed non-Hodgkin’s lymphoma

MTX-HOPE chemotherapy for patients over 70 with relapsed non-Hodgkin’s lymphoma

Posted by on Jun 27, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, etoposide) to treat patients over 70 with non-Hodgkin’s lymphoma (NHL) which had returned after previous treatments. It found that MTX-HOPE was an effective and safe treatment for these patients. Some background NHL is a group of cancers of the...

Read More

The benefits of repeated cytoreductive surgery and hyperthermic peritoneal chemotherapy in advanced colorectal cancer

The benefits of repeated cytoreductive surgery and hyperthermic peritoneal chemotherapy in advanced colorectal cancer

Posted by on May 21, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the benefits of repeated cytoreductive surgery (CRS) and hyperthermic peritoneal chemotherapy (HIPEC) in patients with advanced colorectal cancer. Researchers suggested that repeated treatment improves the survival of patients with advanced colorectal cancer, without an increase in side effects. Some background...

Read More

How effective and safe is high-dose chemotherapy and stem cell transplant for children with lymphoma?

Posted by on Apr 14, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the effectiveness and safety of high-dose chemotherapy and stem cell transplants for children with lymphoma. The study showed that the combination treatment was very effective but that the dose may need to be adjusted for some patients. Some background Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) have very...

Read More

Evaluating brentuximab vedotin for elderly patients with hard to treat Hodgkin lymphoma

Posted by on Mar 24, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) in elderly patients with relapsed or unresponsive Hodgkin lymphoma (HL). This study found that this treatment was effective, although frail patients may be at higher risk for side effects. Some background Most patients with HL respond to front-line...

Read More

Reviewing treatment options for patients with recurrent classical Hodgkin’s lymphoma

Posted by on Mar 16, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This article reviews treatment options for patients with classical Hodgkin's lymphoma (cHL) that came back (relapsed) after chemotherapy. This study found that targeted therapies are becoming more prevalent and that patient outcomes have improved. Some background cHL is a cancer of white blood cells called lymphocytes....

Read More

Have outcomes improved for patients with Hodgkin’s lymphoma who relapse after a stem cell transplant?

Posted by on Mar 16, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with classical Hodgkin’s lymphoma (cHL) that came back after an autologous stem cell transplant (autoSCT). This study found that advancements in treatment have helped improve survival outcomes for patients. Some background Chemotherapy is usually the first-line...

Read More